"Clarithromycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.
| Descriptor ID |
D017291
|
| MeSH Number(s) |
D02.540.576.500.992.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clarithromycin".
Below are MeSH descriptors whose meaning is more specific than "Clarithromycin".
This graph shows the total number of publications written about "Clarithromycin" by people in this website by year, and whether "Clarithromycin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 4 | 4 | 8 |
| 1997 | 5 | 1 | 6 |
| 1998 | 1 | 2 | 3 |
| 1999 | 3 | 3 | 6 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 1 | 3 |
| 2003 | 1 | 2 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 2 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 4 | 2 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 2 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 5 | 6 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 7 | 7 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clarithromycin" by people in Profiles.
-
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 04 18; 14(1):8986.
-
Cut-off value of clarithromycin resistance in the treatment of Helicobacter pylori infection: how low is low? Gut. 2024 01 05; 73(2):374-375.
-
Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
-
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):56-67.
-
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023 Dec; 28(6):e13019.
-
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
-
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
-
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022; 13:1049908.
-
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert Rev Gastroenterol Hepatol. 2023 Jan; 17(1):1-7.
-
Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 02 01; 118(2):269-275.